Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis

Table 1 Characteristics of included studies

Study	Date	Design	Blind method	Follow-up period	Sample size, n	Enrollment period	Cell origin	Delivery approach	MSCs dose	Placebo
Wang JA	2006	RCT	NA	6 months	24	2002.1–2004.10	Autologous bone marrow	Intracoronary injection	(5.86 ± 2.36) × 10⁵/ml × 30 ml	NS
Heldman AW	2013	RCT	Double-blind	12 months	30	NA	Autologous bone marrow	TESI	NA	Vehicle placebo
Zhao XF	2014	RCT	NA	6 months	59	2010.12–2011.12	Allogeneic Umbilical cord	Intracoronary injection	NA	NA
Mathiasen AB	2015	RCT	Double-blind	6 months	60	NA	Autologous bone marrow	TESI	(77.5 ± 67.9) × 10^{^6}	PBS
Xiao W	2016	RCT	NA	12 months	37	2010.3–2011.6	Autologous bone marrow	Intracoronary injection	(4.9 ± 1.7) × 10⁸	NS
Butler J	2016	RCT	Single-blind	6 months	22	2014.6–2016.4	Autologous bone marrow	Intravenous injection	1 × 10⁶/kg	LRS
Perin	2015	RCT	Single-blind	12 months	60	2008.8–2010.6	Allogeneic bone marrow	TESI	25/50/75 × 10⁶	NA
Bartolucci J	2017	RCT	Double-blind	12 months	30	2012.12–2014.6	Allogeneic Umbilical cord	Intravenous injection	1 × 10⁶/kg	Autologous plasma
Bartunek J	2017	RCT	Double-blind	39 weeks	271	2012.12–2015.7	Autologous bone marrow	TESI	NA	NA

RCT randomised controlled trial, TESI transendocardial stem cell injection, LRS lactate Ringer solution, NS normal saline, PBS phosphate buffer saline, NA not available

ISSN: 1757-6512